Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study

SIMPLE SUMMARY: Low cost, reliable predictors of benefit from PARP inhibitors (PARPi) are missing for relapsed BRCA wild-type (WT) ovarian cancer (OC). MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuninetti, Valentina, Ghisoni, Eleonora, Pignata, Sandro, Picardo, Elisa, Raspagliesi, Francesco, Andreetta, Claudia, Maldi, Elena, Artioli, Grazia, Mammoliti, Serafina, Zanchi, Lucia, Sikokis, Angelica, Biglia, Nicoletta, Parisi, Alessandro, Mandato, Vincenzo Dario, Carella, Claudia, Cormio, Gennaro, Marinaccio, Marco, Puppo, Andrea, Paolini, Biagio, Borsotti, Lucia, Scotto, Giulia, Turinetto, Margherita, Sangiolo, Dario, Di Maio, Massimo, Valabrega, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954459/
https://www.ncbi.nlm.nih.gov/pubmed/36831376
http://dx.doi.org/10.3390/cancers15041032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954459/
https://www.ncbi.nlm.nih.gov/pubmed/36831376
http://dx.doi.org/10.3390/cancers15041032

Ejemplares similares